靶向费城染色体样急性淋巴细胞白血病中的衰老干细胞样亚群
费城染色体样B细胞急性淋巴细胞白血病(Ph-like ALL)由诱导组成性激酶信号传导的基因改变驱动,与化疗耐药和高复发风险相关。研究利用批量和单细胞多组学分析,对经靶向抑制剂体内治疗的CRLF2重排或ABL1重排Ph-like ALL患者来源异种移植模型中的残留细胞进行分析,鉴定出TKI耐药亚群及治疗逃逸机制。研究发现Ph-like ALL细胞中存在特定的MYC依赖性,并定义了一个由AP-1转录因子调控、具有衰老相关干细胞样特征的新白血病细胞亚群,该休眠亚群可被BCL-2与JAK/STAT或SRC/ABL通路的双重药理抑制有效根除。
要点
- Ph-like ALL中鉴定出由AP-1转录因子调控的衰老相关干细胞样白血病亚群。
- 该休眠亚群可被BCL-2联合JAK/STAT或SRC/ABL双重药理抑制有效根除。
- 该亚群的单细胞分子特征可预测儿童B-ALL其他高危遗传亚型的不良临床结局。
核心结论
- Ph-like ALL中存在特定的MYC依赖性,并定义了一个由AP-1转录因子调控、具有衰老相关干细胞样特征的新白血病细胞亚群。
- 该休眠ALL亚群可被BCL-2与JAK/STAT或SRC/ABL通路的双重药理抑制有效根除,是一种具有临床相关性的治疗策略。
- 该衰老及干/祖细胞样亚群的单细胞分子特征可预测儿童B-ALL其他高危遗传亚型的不良临床结局,可能具有超越Ph-like ALL的更广泛预后适用性。
研究设计与样本
- 研究使用批量和单细胞多组学分析,对经靶向抑制剂体内治疗的CRLF2重排或ABL1重排Ph-like ALL患者来源异种移植模型中的残留细胞进行图谱分析。
主要发现
- 在最常见的CRLF2重排/JAK通路激活的Ph-like ALL亚型中,临床前研究显示对基于JAK抑制剂的治疗反应不一,提示存在不完全的癌基因依赖。
- ABL类Ph-like ALL亚型似乎优先对靶向SRC/ABL或PDGFRB的抑制剂敏感。
- 研究检测到Ph-like ALL细胞中存在特定的MYC依赖性,并定义了一个由AP-1转录因子调控、具有衰老相关干细胞样特征的新白血病细胞亚群。
- 该休眠ALL亚群可被BCL-2与JAK/STAT或SRC/ABL通路的双重药理抑制有效根除。
- 该衰老及干/祖细胞样亚群的单细胞分子特征可预测儿童B-ALL其他高危遗传亚型的不良临床结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) is driven by genetic alterations that induce constitutive kinase signaling and is associated with chemoresistance and high relapse risk in children and adults. Preclinical studies in the most common CRLF2-rearranged/JAK pathway-activated Ph-like ALL subtype have revealed variable responses to JAK inhibitor-based therapies, suggesting incomplete oncogene addiction and highlighting a need to elucidate alternative biologic dependencies and therapeutic vulnerabilities, whereas the ABL-class Ph-like ALL subtype seems preferentially sensitive to SRC/ABL- or PDGFRB-targeting inhibitors. Which patients may be responsive vs resistant to tyrosine kinase inhibitor (TKI)-based precision medicine approaches remains a critical knowledge gap. Using bulk and single-cell multiomics analyses, we profiled residual cells from CRLF2-rearranged or ABL1-rearranged Ph-like ALL patient-derived xenograft models treated in vivo with targeted inhibitors to identify TKI-resistant subpopulations and potential mechanisms of therapeutic escape. We detected a specific MYC dependency in Ph-like ALL cells and defined a new leukemia cell subpopulation with senescence-associated stem cell-like features regulated by AP-1 transcription factors. This dormant ALL subpopulation was effectively eradicated by dual pharmacologic inhibition of BCL-2 and JAK/STAT or SRC/ABL pathways, a clinically relevant therapeutic strategy. Single cell-derived molecular signatures of this senescence and stem/progenitor-like subpopulation further predicted poor clinical outcomes associated with other high-risk genetic subtypes of childhood B-ALL and thus may have broader prognostic applicability beyond Ph-like ALL.
引用
- Ding YY, Sussman JH, Madden K, et al. Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2025. PMID: 39774844. doi:10.1182/blood.2024026482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。